Home › Ewing Sarcoma › District of Columbia
Ewing Sarcoma clinical trials in District of Columbia
6 studies for Ewing Sarcoma are looking for participants at sites in District of Columbia.
Cities in District of Columbia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
- Children's National Hospital, Washington D.C.
- Childrens National Hospital, Washington D.C.
RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
- Sibley Memorial Hospital, Washington D.C.
Recruiting
Up to age 39 · All sexes · Updated Jul 13, 2026 · NCT06796543Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's National Medical Center, Washington D.C.
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Children's National Hospital, Washington D.C.
RecruitingPhase 1/2
Ages 2 to 30 · All sexes · Updated Feb 3, 2026 · NCT05734066A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's National Medical Center, Washington D.C.
RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.